Institute of Experimental Ophthalmology, Germany; Center of Excellence "Cells in Motion" (CiM), School of Medicine, University of Münster, Albert-Schweitzer-Campus 1, D15, 48149 Münster, Germany.
Institute of Experimental Ophthalmology, Germany; Center of Excellence "Cells in Motion" (CiM), School of Medicine, University of Münster, Albert-Schweitzer-Campus 1, D15, 48149 Münster, Germany.
Prog Retin Eye Res. 2014 Sep;42:145-61. doi: 10.1016/j.preteyeres.2014.06.004. Epub 2014 Jul 4.
Neuroprotection is an emerging challenge in ophthalmology due to the particularly exposed location of retinal neurons and to the steadily increasing rate of intraocular surgical and pharmacological treatments applied to various eye diseases. Within few decades neuroprotection has developed from strongly contested approaches to being recognized and introduced as a potentially clinical application. One of the groups of putative substances for neuroprotection comprises αA- and αB-crystallins, which are types of heat-shock proteins and are considered to be molecular chaperones. The β/γ-crystallins form their own superfamily and are characterized as proteins with a distinct structure containing four Greek key motifs. Besides being abundant in the ocular lens, crystallins are also expressed in both the developing and mature retina. Crystallins are dramatically up-regulated in numerous retinal pathologies, including mechanical injury, ischemic insults, age-related macular degeneration, uveoretinitis, and diabetic retinopathy. Crystallins of the α family are thought to play a crucial role in retinal neuron survival and inflammation. Crystallins of the β/γ superfamily are also small proteins with a possible emerging role in retinal tissue remodeling and repair. One of the typical retinal diseases associated with crystallins is the experimental glaucomatous neuropathy that is characterized by their expression. Another typical retinal disease is the atrophy that occurs after mechanical injury to the optic nerve, which is associated with the need to regrow retinal axons. We have shown in regenerative models in vivo and in vitro that βB2-crystallin actively supports the regenerative growth of cut retinal axons, thereby offering targets for neuroprotective and regenerative treatments. In this review we discuss the discovery that βB2-crystallin is clearly up-regulated in the regenerating retina in vitro. βB2-Crystallin is produced and secreted during axon elongation, while β/γ-crystallins promote axon growth both in vivo and in vitro by acting either directly by uptake into cells, or indirectly by enhancing the production of ciliary neurotrophic factor from astrocytes to synergistically promote axon regrowth. We also discuss methods to induce the continuous production of crystallins at the site of injury and repair based on the use of transfected neural progenitor cells. This review ultimately leads to the conclusion that the postinjury fate of neurons cannot be seen merely as inevitable, but instead should be regarded as a challenge to shaping the neuroprotective and regenerative conditions that promote cell survival and axon repair.
神经保护是眼科学中的一个新兴挑战,这是由于视网膜神经元所处的位置特别容易受到损伤,以及各种眼部疾病的眼内手术和药物治疗的数量不断增加。在短短几十年内,神经保护已从备受争议的方法发展为被认可并被引入潜在的临床应用。神经保护的一类潜在物质包括αA-和αB-晶体蛋白,它们是热休克蛋白的类型,被认为是分子伴侣。β/γ-晶体蛋白形成自己的超家族,其特征是具有独特结构的蛋白质,包含四个希腊关键基序。晶体蛋白不仅在眼部晶状体中大量表达,而且在发育中和成熟的视网膜中也有表达。晶体蛋白在许多视网膜病变中显著上调,包括机械损伤、缺血性损伤、年龄相关性黄斑变性、葡萄膜炎和糖尿病性视网膜病变。α家族的晶体蛋白被认为在视网膜神经元存活和炎症中起着关键作用。β/γ 超家族的晶体蛋白也是小蛋白,在视网膜组织重塑和修复中可能具有新兴作用。与晶体蛋白相关的一种典型的视网膜疾病是实验性青光眼神经病变,其特征是其表达。另一种典型的视网膜疾病是视神经机械损伤后发生的萎缩,这与需要再生视网膜轴突有关。我们在体内和体外的再生模型中表明,βB2-晶体蛋白积极支持切割的视网膜轴突的再生性生长,从而为神经保护和再生治疗提供了靶点。在这篇综述中,我们讨论了βB2-晶体蛋白在体外再生视网膜中明显上调的发现。βB2-晶体蛋白在轴突伸长过程中产生和分泌,而β/γ-晶体蛋白通过直接摄取细胞或间接增强星形胶质细胞产生睫状神经营养因子来促进轴突生长,从而在体内和体外均促进轴突生长,以协同促进轴突再生。我们还讨论了基于转染神经祖细胞在损伤和修复部位连续产生晶体蛋白的方法。这篇综述最终得出结论,神经元的损伤后命运不能仅仅被视为不可避免的,而应被视为塑造促进细胞存活和轴突修复的神经保护和再生条件的挑战。